This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Bifidobacterium longum infantis is a probiotic indicated in the treatment of infectious and non-specific diarrhea.
- Generic Name
- Bifidobacterium longum infantis
- DrugBank Accession Number
- DB14222
- Background
Not Available
- Type
- Biotech
- Groups
- Approved, Experimental
- Synonyms
- Bifidobacterium infantis
- Bifidobacterium infantis whole
- Bifidobacterium lactentis whole
- Bifidobacterium liberorum whole
- Bifidobacterium longum bv. infantis whole
- Bifidobacterium longum infantis whole
- Bifidobacterium longum subsp. infantis
- Bifidobacterium longum subsp. infantis whole
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Diarrhea Combination Product in combination with: MRx-4DP0004 (DB15751), Lactobacillus plantarum (DB11360), Zinc sulfate (DB09322) •••••••••••• •••••••••• Used in combination to treat Infectious diarrhoea Combination Product in combination with: Zinc sulfate (DB09322), MRx-4DP0004 (DB15751), Lactobacillus plantarum (DB11360) •••••••••••• •••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADET Bifidobacterium longum infantis (10 mg/10ml) + Lactobacillus plantarum (14.2 mg/10ml) + MRx-4DP0004 (6.6 mg/10ml) + Zinc sulfate heptahydrate (15 mg/10ml) Suspension Oral BERKO İLAÇ VE KİMYA SAN. A.Ş. 2017-09-26 Not applicable Turkey 
Biovi Total Beauty Bifidobacterium longum infantis (4 mg/1) + Avobenzone (30 mg/1mL) + Homosalate (90 mg/1mL) + Octisalate (45 mg/1mL) + Octocrylene (26 mg/1mL) + Oxybenzone (20 mg/1mL) Kit Oral; Topical Procter And Gamble 2012-12-23 2014-12-23 US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EF3U3H7I76
- CAS number
- Not Available
References
- General References
- TITCK Product Information: Biober-Zn (Bacterial Culture and Zinc Sulfate) Oral Suspension [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Dyspepsia Chronic / Irritable Bowel Syndrome (IBS) 1 4 Completed Treatment Irritable Bowel Syndrome (IBS) 1 3 Completed Treatment Irritable Bowel Syndrome (IBS) 1 2, 3 Completed Prevention Diarrhea / Diarrhoea 1 2, 3 Unknown Status Prevention Crohn's Disease (CD) / Ulcerative Colitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Oral Kit Oral; Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at July 04, 2018 22:41 / Updated at May 14, 2021 01:06